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Summary The cell kinetics of 82 squamous cell carcinomas of the head and neck were studied by in vivo
administration of the thymidine analogue, bromodeoxyuridine (BrdUrd). Ploidy, BrdUrd labelling index (LI),
duration of S-phase (Ts), potential doubling time (Tpot) and S-phase fraction (SPF) were measured by flow
cytometry on 50 gtm paraffin embedded sections. The range of values obtained compared well with other in
vivo cell kinetic studies of head and neck cancer. Aneuploid tumours had a significantly higher BrdUrd
labelling index and SPF, and a short Tpot than diploid tumours. To validate the use of 50ytm sections for
measuring cell kinetic parameters by flow cytometry a comparison of values obtained by 50 im sections and
small blocks of tissue was made. No significant difference was found between the two methods. Re-
producibility of values between two consecutive thick sections was also good. We conclude that reproducible
cell kinetic measurements can be made in tumour samples using 50 jLm sections of BrdUrd labelled tissue.
The kinetics of tumour growth may be an important factor
influencing tumour aggression and the course of malignant
disease. Kinetic parameters may therefore be of value in
assessing prognosis and the response of tumours to cytostatic
treatment (Steel, 1977; Meyer, 1982). Cell kinetic studies in
man, until recently, have been limited to in vitro investiga-
tions because of the ethical constraints of administering
radioactive DNA precursors to patients. Tritiated thymidine
labelling of freshly excised tissue followed by autoradiog-
raphy has been widely used (Gentili et al., 1981; Brandt &
Olsson, 1987; Courdi et al., 1989; Meyer & Bauer, 1975). The
development of flow cytometric methods for measuring DNA
content, particularly in paraffin embedded archival material,
has resulted in DNA ploidy and S-phase fraction analysis
being performed for many tumour types (Cornelisse et al.,
1987; Armitage, 1985; Feichter et al., 1987). Static measure-
ments such as these provide limited information and may not
give a true estimate of a tumour's proliferative state. Tem-
poral kinetic parameters such as cell cycle phase duration
and potential doubling time may provide a more meaningful
estimate of tumour growth.
The potential doubling time (Steel & Bensted, 1965) is a
measure of the rate of increase in the number of proliferating
cells of a tumour. The equation derived by Steel takes
account of the non-proliferating cells of a tumour but not
cells lost from the cycling pool through death, differentiation
or metastasis. Thus the Tpot represents an index of a
tumour's capacity to grow and may be a clinically useful
parameter. It has been suggested that radiotherapy and
chemotherapy regimes can be designed on the basis of Tpot
values to optimise therapeutic response for individual
patients (Fowler, 1985; Thames et al., 1983; Begg et al.,
1990). The clinical application of cell kinetic information
requires a technique which generates results rapidly within a
day or two of biopsy. The use of tritiated thymidine and
autoradiography is therefore unsuitable.
The development of a monoclonal antibody to bromo-
deoxyuridine (BrdUrd) (Gratzner, 1982), a thymidine anal-
ogue which can be safely administered to patients, together
with a technique that simultaneously measures incorporated
bromodeoxyuridine (BrdUrd) and DNA content by flow
cytometry (Dolbeare et al., 1983) has facilitated the study of
human tumour cell kinetics. Begg et al. (1985) further
developed the technique to calculate the potential doubling
time of tumours from a single biopsy taken a number of
hours after BrdUrd administration thus obviating the need
for multiple biopsies.
Here we present preliminary data on the labelling index,
duration of S-phase and potential doubling times of 82
squamous cell tumours from the head and neck which form
part of a prospective study to determine whether cell kinetic
data, in particular the potential doubling time, have any




Patients who were due to undergo resection of a squamous
cell tumour of the head and neck region were asked to
participate in the study. One hundred and four patients with
previously untreated and recurrent tumours from a variety of
sites received BrdUrd. Permission to administer BrdUrd to
patients was granted by the ethical committee at the Royal
Liverpool Hospital. BrdUrd suitable for human subjects was
obtained from Takeda Chemical Industries, Osaka, Japan
and later from the Department of Pharmacy at the Univer-
sity of Strathclyde, Glasgow. The BrdUrd was administered
as an intravenous infusion over 15 min at a concentration of
200 mg in 100 ml of 0.9% saline, 6-8 h before expected
resection of the surgical specimen.
Sample preparation
On receipt of the specimen, a sample of tumour up to 1 cm3
in volume was taken close to the margin of the tumour and
fixed in cold 70% alcohol. After 2-3 days half the sample
was processed to paraffin wax while the remainder was left in
alcohol. Thick 50 ytm sections were dewaxed and rehydrated
through graded alcohols to water. The sections were disagg-
regated according to the method described by Hedley et al.
(1985) using 0.5% pepsin pH 1.5 at 37°C for 30 min. The
digest was washed twice in phosphate buffered saline (PBS)
and then filtered through a 40 Lm mesh. Disaggregation of
the remaining fixed specimen was performed in parallel by
rehydrating to water, mincing the tumour finely as possible
with a scalpel and disaggregating as above with pepsin. Thin
4 lim sections were cut from all paraffin blocks and stained
with haematoxylin and eosin to confirm the presence of
tumour and assess the relative proportions of tumour to
normal tissue.
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BrdUrd/DNA staining
The nuclear preparation was denatured by 2 M HCl at room
temperature for 30 min. 0.1 M Borax pH 8.5 was used to
neutralise the acid. The samples were then washed twice, first
with PBS and then with PBS containing 1% bovine serum
albumin and 0.1% Tween 20 (PBT). The nuclear suspension
was then incubated with 100 gl of mouse anti-BrdUrd (Dako
Ltd, High Wycombe) at a dilution of 1/30 for 1 h at room
temperature, washed twice in PBT, followed by incubation
with 100lil of goat anti mouse-FITC conjugated antibody
(Sigma Chemical Co, Poole) for 30 min at room temperature
at a dilution of 1/40. After washing thoroughly in PBT, then
PBS, the samples were stained with propidium iodide at a
concentration of 10 ig ml' for 30 min at room temperature
or at 4°C overnight.
Flow cytometric analysis
Flow cytometric analysis (FCM) of the samples was per-
formed using a Coulter Epics Profile II flow cytometer fitted
with a 15 mW air cooled argon ion laser emitting at 488 nm.
Green and red fluorescent emissions were collected through a
525 nm band pass and 610 nm long pass filter respectively.
Data acquisition was in list mode and between 10,000-
100,000 nuclei were recorded. Aggregates of whole nuclei
and nuclear debris were excluded from the data list by gating
on the DNA area vs peak signal.
Calculation ofcell cycle parameters
A typical flow cytometric output for an aneuploid tumour is
illustrated in Figure 1.
The duration of S-phase (Ts) and the potential doubling
time (Tpot) was calculated by the method developed by Begg
et al. (1985). The relative movement, a measure of how far
labelled cells have travelled through the S-phase in the labell-
ing time, and the BrdUrd labelling index (LI) i.e. the number
of BrdUrd labelled cells expressed as a percentage of the
total cell population, were both calculated by on-screen
analysis using the Epics Profile II software. When calculating
the BrdUrd LI the number of labelled cells in Gl was halved
to correct for the division that these cells had undergone
since being labelled. For aneuploid tumours the combined LI
of aneuploid and diploid cells (total LI) and that of the
aneuploid component only was calculated. When calculating
the total LI cells that had moved into GI were not halved as
before. A total LI was also calculated in this way for diploid
tumours so that aneuploid and diploid tumours could be
compared. This results in the small difference between LI and
total LI for diploid tumours seen in Table II. The relative
movement and the tumour LI were used to calculate values
of Ts and Tpot using equations (1) and (2) below. All Tpot
calculations for aneuploid tumours were made using the LI





Tpot = A- (2)
LI
where t is the labelling time and A is a correction factor for
the non-linear age distribution of cells through the cell cycle.
It was assumed to be 0.8 (Steel, 1977).
Calculation of lablling index and relative movement was
often difficult for aneuploid tumours where there was overlap
with a diploid population. In these cases diploid cells with
labelled late S-phase and G2M nuclei overlapped with aneup-
loid cells labelled in the GI and S-phase. Consequently the
labelling index of the aneuploid component was artificially
high and the relative movement was biased towards the
aneuploid GI causing the Ts to be longer than its 'true'
value. Where there was a significant proportion of diploid
cells in aneuploid tumour samples (over 80% of cases),
labelled diploid cells with late S and G2M DNA content were
excluded from the analysis. This was achieved by delineating
the area between the end of the GI aneuploid peak and the
end of the diploid G2M peak and excluding the labelled cells
in this area. Thus they made no contribution to the LI and
relative movement. In aneuploid tumours where there was
low labelling associated with the diploid component this
procedure made little difference to the LI and the Ts cal-
culated, but in those with high labelling the LI and Ts could
be significantly reduced. The procedure was made easier
when there was a clear demarcation between the labelled
diploid and aneuploid cohorts of cells. S-phase fractions were
measured from DNA histograms generated for BrdUrd/DNA
analysis using a simple 'rectangular fit' model provided by
Cytologic software, Coulter Electronics. These were corrected
for background by exponential subtraction.
Reproducibility
Reproducibility of the method was assessed by measuring cell
kinetic parameters on 12 pairs of consecutive 50,Lm sections.
Agreement between cell kinetic parameters measured from
50 ltm sections and 0.5 cm3 tissue blocks from the same
tumour sample was also examined. Interobserver variation
was monitored by comparing measurement of the BrdUrd






















Figure 1 Flow cytometric output of an aneuploid squamous cell
tumour. a, DNA Histogram b, Bivariate cytogram of BrdUrd
uptake vs DNA content.
I
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Table I Comparison of measurements made from: (1) consecutive
50gm sections; (2) sections vs tissue blocks; (3) LI by 2 independent
observers, by the Bland-Altman Method; all given as ratios. Statistics
describe the distribution of these ratios
Mean ratio (95% CI.) s.d.
Section 1/ LI 1.05 (0.97-1.13) 0.12
Section 2 (n = 12) Ts 1.07 (0.99-1.16) 0.13
Section/ LI 1.05 (0.89-1.21) 0.47
Biopsy (n = 37) Ts 1.09 (0.99-1.19) 0.31
Observer 1/ LI 1.13 (1.07-1.19) 0.16
Observer 2 (n = 37)
Statistical analysis
Differences in cell cycle parameters between aneuploid and
diploid tumours were compared by the Mann Whitney U test
and association between SPF and BrdUrd labelling index
tested by the Spearman rank correlation test. Reproducibility
between consecutive 50,m sections and agreement between
cell cycle parameters measured for 50 gm sections and tissue
blocks was assessed by a modification of the Bland-Altman
technique, which can detect systematic error in one of the
methods while allowing for variation due to tumour




One hundred and four patients received BrdUrd. One hund-
red and ten samples were collected, six patients having
tumour at more than one site. Cell cycle parameters were
successfully measured in 82 samples (75%). The main reason
for failure was lack of or insufficient tumour in the sample
(25 cases) followed by poor BrdUrd staining profiles (three
cases). However 15 of these samples had sufficient tumour
present to allow ploidy status to be determined.
Reproducibility
Reproducibility data using the Bland-Altman technique are
summarised in Table I. The mean ratios which ideally should
be one indicate whether either set of results exceeds the other
overall. The Standard Deviation (s.d.) indicates the degree of
spread about the mean and thus a small figure indicates less
tendency for the pairs of estimates to differ markedly.
Reproducibility between consecutive thick sections was
good for both LI and Ts. This was also the case for 50 gm
sections and tissue blocks with perhaps 50 gAm sections pro-
ducing slightly longer Ts values but this was not significant.
Inter observer variation in the measurement of labelling
indices was low. Calculation of the LI was performed in
exactly the same way by each observer however there was a
tendency for one observer (PS) to estimate the LI higher than
the other (GF). The confidence interval for this difference
was from 7-19% of the mean of the two estimates obtained.
Cell kinetic parameters
The cell kinetic parameters for all tumours as measured on
50gm tissue sections are summarised in Table II. Labelling
indices varied from 1.2% to 30% with a median of 8.0%.
The duration of S-phase ranged from 7.3 h to 37.5 h with a
median of 13.7 h and the resulting potential doubling times
varied from 1.2 days to 40.9 days with a median of 6.2 days.
Fifty-two tumours (63.4%) were aneuploid and 30 (36.6%)
were diploid. The median labelling indices of aneuploid and
diploid tumours were 9.5% and 5.0% respectively, aneuploid
tumours having a significantly higher labelling index than
diploid tumours (U = 730 P<0.01). This was still true when
total labelling indices were compared where the labelling
index of both tumour and normal tissue is measured. This
parameter represents a fairer comparison between diploid
and aneuploid tumours. The duration of S-phase was similar
for both ploidy groups. The potential doubling times of
aneuploid tumours were significantly shorter than diploid
tumours with medians of 5.0 and 7.7 days respectively
(U = 1705 P<0.01).
SPFanalysis
S-phase analysis was performed successfully on 69 tumours,
13 histograms of aneuploid tumours being unsuitable for
analysis. The median SPF for all tumours was 11.5%. The
SPF of aneuploid tumours was significantly higher than that
of diploid tumours (U = 579, P<0.01), (Table II). The
correlation between the BrdUrd labelling index and S-phase
fraction was poor (r = 0.67) considering they are supposedly
measuring the same parameter. SPF was on average 1.8 times
greater than the BrdUrd labelling index.
Discussion
The measurement ofcell kinetic parameters in vivo in humans
has only recently become possible using the thymidine
analogue, bromodeoxyuridine (BrdUrd). The method deve-
loped by Begg et al. (1985) to measure LI, Ts and Tpot
requires a single biopsy only, at a measured time interval
after administration of BrdUrd. BrdUrd can be given several
hours before a scheduled operation or biopsy with minimal
disruption to normal routine and little extra workload. For
these reasons in vivo cell kinetic studies have become a
feasible alternative to in vitro labelling of tumour fragments.
More detailed cell kinetic information such as the duration of
other phases of the cell cycle and growth fraction still require
multiple biopsies.
The rationale for cell kinetic studies arises from observ-
ations that the growth characteristics of a tumour may influ-
ence prognosis and the curative potential of radiotherapy and
chemotherapy. High S-phase fractions and abnormal DNA
content have been shown to correlate with reduced survival
in a wide range of tumours (Friedlander et al., 1984; Volm et
al., 1985) including some head and neck tumours (Holm,
1982; Franzen et al., 1986) Thymidine labelling indices (TLI)
have been shown to have some prognostic value, particularly
Table II Median and range of values of kinetic data for diploid and
aneuploid tumours
Mann-Whitney
All Diploid Aneuploid (dip vs aneu)
LI (%) 8.0 5.0 9.5 P<0.01
(1.2-30.0) (1.2-12.2) (3.7-30.0)
TOTAL (%) 6.9 5.6 7.7 P<0.01
LI (1.3-21.9) (1.3- 14.6) (2.3-21.9)
Ts (h) 13.7 13.5 13.8 NS
(7.3-37.5) (7.3-27.6) (8.0-37.5)
Tpot (days) 6.2 7.7 5.0 P<0.01
(1.2-40.9) (3.1 -40.9) (1.2-33.7)
SPF (%) 11.5 7.9 14.8 P<0.01
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in breast cancer where high TLI correlates with reduced
survival (Meyer & Hixon, 1979; Gentili et al., 1981) and may
also predict tumour radio and chemosensitivity (Silvestrini et
al., 1984). The relationship between TLI and prognosis is not
so well established in head and neck cancer where unlike in
breast cancer the median TLI fails to divide patients into two
groups with significantly different outlook (Courdi et al.,
1988). However Chauvel et al. (1989) showed in a series of
head and neck tumours, that choosing a value above the
median TLI as a cut-off point identified a small group of
patients with significantly reduced survival when the median
failed to do so.
The results obtained in this study are similar to the limited
number of in vivo cell kinetic studies published to date. The
median labelling index of 8.0% compares well with the 7.8%
observed by Wilson et al. (1988) after in vivo BrdUrd labell-
ing of nine head and neck tumours. Other in vivo studies
employing tritiated thymidine have quoted slightly higher
values ranging from 11.7-28.6% (Bresciani et al., 1974;
Sakuma, 1980) but the sample sizes in these studies were very
small. Much larger cohorts of patients have been studied
using in vitro thymidine labelling. Three such studies
(Chauvaudra et al., 1979; Silvestrini et al., 1984; Chauvel et
al., 1989) reported a median value of 11% for head and neck
tumours. Agreement between labelling indices determined
from in vitro and in vivo labelling experiments is difficult to
assess, but indirect evidence from simple comparisons of
separate studies show the range of values are comparable.
Studies specifically addressing the problem have reported
good correlation between values on the whole, but with some
instances of underestimation of the Li in vitro (Denekamp &
Kallman, 1973; Chauvaudra et al., 1979). Whether or not the
in vitro LI truly reflects the actual in vivo labelling index, its
value as a prognostic marker, at least in some tumours, is
well established and still continues to be widely used.
The median Ts measured in this study of 11.5 h is similar
to that previously reported for oral cancers (Sakuma, 1980;
Silvestrini et al., 1984). Recent in vivo studies have reported
short mean Ts values of between 10-12 h and short median
potential doubling times of 4-5 days which agree well with
our values (Wilson et al., 1988; Begg et al., 1990).
It has been suggested that fast growing tumours may be
more responsive to cytostatic therapy presumably because a
large proportion of cells are in cycle. Feichter et al. (1987)
observed that although the majority of tumours which failed
to respond to therapy had a low SPF, there was a small
group of non-responders with high SPF. One possible reason
for this is that the cell regeneration rate is in excess of cell
destruction, significant cell repopulation taking place in
between treatment periods. For this reason conventional
radiotherapy regimes may be unsuitable for fast growing
tumours. An accelerated course of treatment where the treat-
ment time is shortened from 4 weeks to 3 weeks or less may
be more suitable in these cases (Thames et al., 1983; Fowler,
1985). Such aggressive treatment presents a greater risk to
the patient and may necessitate longer periods of hospitalisa-
tion. The measurement of cell cycle parameters, in particular
the potential doubling time, for individual patients would
identify those that may benefit from accelerated radio-
therapy. Similarly, chemotherapy for patients with advanced
head and neck cancer could be limited to those patients who
are most likely to respond, sparing potential non-responders
form debilitating chemotherapy regimes.
It has been proposed that tumours with a potential doubl-
ing time of 5 days or less may benefit from accelerated
fractionation (Thames et al., 1983; Fowler, 1985). Results for
accelerated radiotherapy have been promising, particularly
when combined with hyperfractionation (multiple fractions
per day), and given over a continuous 12 day period
(Continuous hyperfractionated accelerated radiotherapy -
CHART) (Saunders & Dische, 1986). A multi-centre ran-
domised trial has recently begun to test the efficacy of
CHART compared with conventional treatment. It is hoped
that cell kinetic data will also be available in those centres
currently undertaking BrdUrd studies. Preliminary data from
a similar accelerated radiotherapy trial for head and neck
cancer which begun in 1986 has shown that there was im-
proved local control of fast growing tumours as measured by
in vivo iododeoxyuridine (IUdR) labelling when given
accelerated treatment compared to conventional treatment
(Begg et al., 1990). Using the suggested cut-off point of 5
days to discriminate between quickly and slowly growing
tumours, 28 tumours out of 82 in our study qualified as
candidates for accelerated treatment. Twenty-five of these
tumours were aneuploid, three were diploid. The potential
doubling time of aneuploid tumours was significantly less
than that of diploid tumours which may explain the observa-
tion that aneuploid tumours are often more responsive to
therapy (Franzen et al., 1986; Barlogie et al., 1987; Guo et
al., 1989). We have previously reported that in advanced
unresectable squamous carcinoma of the head and neck there
was a significant prolongation of survival in patients with
aneuploid tumours compared with patients with diploid
tumours when treated with cisplatin (Cooke et al., 1990).
However a recent meta analysis of published data from six
separate head and neck ploidy studies representing 1047 cases
has cast doubt on the prognostic value of tumour DNA
content in head and neck tumours other than in oral cancer
(Stell, 1991).
As well as its potential use as a indicator of radio- and
chemosensitivity the potential doubling time may be useful in
assessing prognosis. Evidence suggests that tumours with
short potential doubling times have shorter relapse free inter-
vals and vice versa (Trott & Kummermehr, 1985). One might
expect Tpot data to have greater predictive power with
regard to prognosis and response to therapy than labelling
indices since they represent a dynamic measure conveying
more accurate information about tumour growth potential.
However the superiority of Tpot over labelling index and
other static measures of proliferation like SPF and ploidy
remains to be proven. The discrepancy between BrdUrd LI
and SPF seen in this study is consistent with other workers
observations and occurs due to the presence of cells with
S-phase DNA content that have failed to take up the DNA
label (Allison et al., 1985; Wilson et al., 1985). These cells
may have simply arrested in S-phase or are synthesising
DNA at such a slow rate that the short exposure time of the
DNA label is insufficient to allow any detectable incorpora-
tion to take place.
In this study cell kinetic measurements obtained from
50pm sections were similar to those obtained from small
blocks of tissue, and reproducibility between consecutive
50,um sections was good thus validating their use for cell
kinetic studies. The main advantage of thick sections is that
only a small piece of tissue is used allowing measurements of
the same or other tumour related factors to be repeated. It
also provides the opportunity to separate tumour from nor-
mal stromal and inflammatory tissue such that more accurate
cell kinetic measurements can be made on a predominance of
tumour cells. Finally the BrdUrd LI can be measured
immunohistochemically on 4,tm sections in parallel with flow
cytometric measurements to determine the degree of concor-
dance between the two methods.
The results from this pilot study indicate that cell kinetic
data can be achieved in the majority of head and neck
cancers, and further studies are under way to assess their
clinical significance.
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